Menu
Close
Patient Fitness in AML
The use of fractionated doses of MYLOTARG significantly* improves EFS and RFS in patients with de novo AML compared with standard front-line chemotherapy1
MYLOTARG is administered as an IV infusion over a 2-hour period on days 1, 4, and 7 in combination with daunorubicin (DNR) infused over 30 minutes on days 1 to 3 and cytarabine (AraC) by continuous infusion on days 1 to 7.
Daily MYLOTARG dose capped at one 5 mg vial.
For patients who do not experience a complete remission (CR)† after induction, a second induction may be required. MYLOTARG should not be administered during a second induction if a second induction is required2
For patients experiencing a complete remission† after induction, up to two consolidation courses are recommended.2
*p values: EFS, p=0.0002; RFS, p=0.0006; MYLOTARG+ chemotherapy vs chemotherapy alone. Median OS was higher with MYLOTARG+ chemotherapy vs chemotherapy alone, but the difference was not statistically significant.
†Defined as <5% blasts in a normocellular marrow and an ANC of >1.0 × 109 cells/L with a platelet count of ≥100 × 109/L in the peripheral blood in the absence of transfusion. Original study allowed consolidation for patients with a complete remission with incomplete platelet recovery (CRp) but dosing modifications preclude the use of MYLOTARG for consolidation in patients with a platelet count of < 100,000/mm3.
For additional adminstration information on use in pregnancy, pre-medication, reconstitution and monitoring during infusion, please click here
Download the Pharmacy Guide for information for pharmacists on MYLOTARG treatment. SmPC should be consulted for full guidance
Download the HCP dosing summary which is a guide to treatment with MYLOTARG. SmPC should be consulted for full guidance.
AML, acute myeloid leukaemia; ANC, absolute neutrophil count; CR, complete remission; EFS, event-free survival; HCP, Healthcare Professional; IV, intravenous; OS, overall survival; RFS, relapse-free survival; SmPC, Summary of Product Characteristics
References:
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024